|Articles|January 14, 2009
Ipsen says FDA extending review date for Reloxin
Chicago - Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.
Advertisement
Chicago
- Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.
Ipsen also says the FDA confirmed the manufacturing process for the product in the Wales facility is in compliance, according to Reuters.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Dermatology Conferences and Meetings Calendar: December 2025
4
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
5
